Insider Buying: Sanofi SA (NYSE:SNY) Major Shareholder Acquires $1,300,000.00 in Stock

Sanofi SA (NYSE:SNY) major shareholder Sanofi acquired 81,250 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The shares were bought at an average price of $16.00 per share, with a total value of $1,300,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Sanofi also recently made the following trade(s):

  • On Tuesday, June 9th, Sanofi sold 120,234 shares of Sanofi stock. The shares were sold at an average price of $597.48, for a total value of $71,837,410.32.
  • On Friday, May 29th, Sanofi sold 20,421,899 shares of Sanofi stock. The shares were sold at an average price of $509.85, for a total value of $10,412,105,205.15.

Shares of SNY opened at $52.45 on Friday. The stock has a market capitalization of $131.34 billion, a price-to-earnings ratio of 16.76, a price-to-earnings-growth ratio of 2.41 and a beta of 0.67. Sanofi SA has a 1 year low of $37.62 and a 1 year high of $55.00. The business’s 50 day simple moving average is $51.68 and its 200-day simple moving average is $48.67. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85.

Institutional investors and hedge funds have recently modified their holdings of the company. CFM Wealth Partners LLC purchased a new stake in shares of Sanofi during the 1st quarter worth approximately $25,000. AlphaCore Capital LLC purchased a new stake in shares of Sanofi during the 1st quarter worth approximately $29,000. Citizens Financial Group Inc RI purchased a new stake in shares of Sanofi during the 1st quarter worth approximately $44,000. Allworth Financial LP raised its holdings in shares of Sanofi by 128.5% during the 2nd quarter. Allworth Financial LP now owns 1,092 shares of the company’s stock worth $56,000 after acquiring an additional 614 shares in the last quarter. Finally, Beese Fulmer Investment Management Inc. purchased a new stake in shares of Sanofi during the 2nd quarter worth approximately $58,000. 7.04% of the stock is currently owned by institutional investors and hedge funds.

SNY has been the subject of several recent analyst reports. Morgan Stanley restated an “overweight” rating on shares of Sanofi in a research note on Tuesday, June 9th. Zacks Investment Research upgraded Sanofi from a “hold” rating to a “buy” rating and set a $50.00 price target for the company in a research note on Monday, May 18th. UBS Group restated a “buy” rating on shares of Sanofi in a research note on Tuesday, May 26th. Barclays restated an “equal weight” rating on shares of Sanofi in a research note on Tuesday, April 28th. Finally, JPMorgan Chase & Co. restated an “overweight” rating on shares of Sanofi in a research note on Friday. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Sanofi presently has a consensus rating of “Buy” and a consensus price target of $54.00.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Recommended Story: Why are percentage decliners important?

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.